HLA-DR Mouse monoclonal Antibody IgG1
Fig1: Western blot analysis of HLA-DR on Raji cell lysate using anti-HLA-DR antibody at 1/1,000 dilution.
Fig2: Immunohistochemical analysis of paraffin-embedded human tonsil tissue using anti-HLA-DR antibody. Counter stained with hematoxylin.
Fig3: Immunohistochemical analysis of paraffin-embedded human lung cancer tissue using anti-HLA-DR antibody. Counter stained with hematoxylin.
Host Species; Species ReactivityMouse; Human
Application SummaryWB, IHC, FC
Purification; FormulationPeptide affinity purified; 1*TBS (pH7.4), 0.5%BSA, 50%Glycerol. Preservative: 0.05% Sodium Azide.; Liquid form.
ALTnamesHLA class II histocompatibility antigen, DR alpha chain, MHC class II antigen DRA
BackgroundMajor histocompatibility complex (MHC) class II molecules destined for presentation to CD4+ helper T cells is determined by two key events. These events include the dissociation of class II-associated invariant chain peptides (CLIP) from an antigen binding groove in mhc ii-a/b dimers through the activity of MHC molecules HLA-DM and -DO, and subsequent peptide antigen binding. Accumulating in endosomal/lysosomal compartments and on the surface of B cells, HLA-DM, -DO molecules regulate the dissociation of CLIP and the subsequent binding of exogenous peptides to HLA class II molecules (HLA-DR, -DQ and -DP) by sustaining a conformation that favors peptide exchange. RFLP analysis of HLA-DM genes from rheumatoid arthritis (RA) patients suggests that certain polymorphisms are genetic factors for RA susceptibility. HLA-B belongs to the HLA class I heavy chain paralogs. Class I molecules play a central role in the immune system by presenting peptides derived from the endoplasmic reticulum lumen. HLA-B and -C can form heterodimers consisting of a membrane anchored heavy chain and a light chain (β-2-Microglobulin). Polymorphisms yield hundreds of HLA-B and -C alleles.(M1701-5)